10KSB 1 etpt10ksbdec312003ev.htm <B>FORM 10-K


FORM 10-KSB


X    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES    EXCHANGE ACT OF 1934  


For the fiscal year ended December 31, 2003.


OR


      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  


For the transition period from  ____________________    to   _____________________                               


 Commission File Number 000-28790


ENTERPRISE TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

           NEVADA

 

       87-0429962B

                  (State or other jurisdiction of

                    incorporation or organization)

 

         (I.R.S. Employer

     Identification Number)

 


216 – 1628 West 1st Avenue,

Vancouver, B.C., V6J 1G1,

TEL: (604) 659-5004

(Address, including zip code, and telephone number,

including area code, of registrant’s principal executive offices)

 

Securities registered pursuant to Section 12(b) of the Act:

 

                     Title of Each Class

 

Name of Each Exchange on Which Registered

                     Common Stock, $.00001 par value per share

 

OTC Bulletin Board


Securities registered pursuant to Section 12(g) of the Act: None


Indicate by check mark whether the registrant: (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing for the past 90 days. Yes [X] No [_]


Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-B is not contained herein, and will not be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB [X]


Revenues for last fiscal year were $0.00


Aggregate market value of Common Stock, $0.00001 par value, held by non-affiliates of the registrant as of March 25, 2004: $12,107,498. Number of shares of Common Stock, $0.00001 par value, outstanding as of March 29, 2004, 2003: 161,223,308.


Transitional Small Business Disclosure Format:  Yes [   ] No [X]



TABLE OF CONTENTS


ENTERPRISE TECHNOLOGIES, INC.

ANNUAL REPORT ON FORM 10-KSB

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2003



                                                                             

PART I

PAGE

 

Item 1.   Description of Business

3


Item 2.   Description of Property

6


Item 3.   Legal Proceedings   

6


Item 4.   Submissions of Matters to a Vote of Security Holders   

7

 

PART II

 

Item 5.    Market for Common Equity and Related Stockholder Matters

7


Item 6.    Management's Discussion and Analysis or Plan of Operations

8


Item 7.    Financial Statements

11


Item 8.    Changes in and Disagreements with Accountants on Accounting and

 Financial Disclosure

26


Item 8a

Controls and Procedures

26


PART III


Item 9.    Directors, Executive Officers, Promoters and Control Persons;

Compliance with Section 16(a) of the Exchange Act

26


Item 10.

 Executive Compensation

26


Item 11.

 Security Ownership of Certain Beneficial Owners and Management

27


Item 12.  Certain Relationships and Related Transactions

28


Item 13.  Exhibits and Reports on Form 8-K

28


Item 14.  Principal Accountant Fees and Services

30


 Signatures

31


 Certifications

33


 Exhibits

34



PART I


ITEM 1.  DESCRIPTION OF BUSINESS


Cautionary Statement Pursuant to Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995:

 

Except for the historical information presented in this document, the matters discussed in this Form 10-KSB for the three month and nine month periods ending September 30, 2003, and specifically in the items entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations", or otherwise incorporated by reference into this document, contain "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are identified by the use of forward-looking terminology such as "believes", "plans", "intend", "scheduled", "potential", "continue", "estimates", "hopes", "goal", "objective", expects", "may", "will", "should" or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. The safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, apply to forward-looking statements made by the Company.


The reader is cautioned that no statements contained in this Form 10- KSB should be construed as a guarantee or assurance of future performance or results. These forward-looking statements involve risks and uncertainties, including those identified within this Form 10-KSB. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. These forward-looking statements are based on current expectations, and the Company assumes no obligation to update this information. Readers are urged to carefully review and consider the various disclosures made by the Company in this Form 10-KSB and in the Company's other reports filed with the Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that may affect the Company's business.


The Company


Enterprise Technologies, Inc. (the "Company" or "Enterprise") pioneered the MedCare Program, a non-invasive, non-pharmaceutical treatment program for patients suffering from urinary incontinence and other pelvic disorders, including pelvic pain, chronic constipation, fecal incontinence and disordered defecation.

Enterprise is currently (1) searching for potential joint venture partners that have existing operating infrastructures to which the MedCare Program can be added as an ancillary service and (2) is seeking to develop additional revenue streams through the further development and commercial exploitation of the Company's current intellectual property base and or the acquisition of additional technologies.

The Company, a Nevada Corporation, has an authorized capital of 301,000,000 shares of which 300,000,000 shares are $0.00001 par value common stock, with 161,223,308 outstanding, and 1,000,000 shares are $0.25 par value preferred stock, of which none are outstanding.

Employees


At December 31, 2003, the Company employed 0 full-time and 3 part-time persons. To the best of the Company’s knowledge, none of the Company’s officers or directors is bound by restrictive covenants from prior employers. None of the Company’s employees are represented by labor unions or other collective bargaining groups. We consider relations with our employees to be good. We plan to retain and utilize the services of outside consultants as the need arises.


Risk Factors


We have sought to identify what we believe to be the most significant risks to our business.  However, we cannot predict whether, or to what extent, any of such risks may be realized nor can we guarantee that we have identified all possible risks that might arise. Investors should carefully consider all of such risk factors before making an investment decision with respect to our Common Stock. We provide the following cautionary discussion of risks, uncertainties and possible inaccurate assumptions relevant to our business. These are factors that we think could cause our actual results to differ materially from expected results. Other factors besides those listed here could adversely affect us.


Lack of Operating History:  


Because of our limited operating history and lack of past profitability, you may lose your investment if we are unable to successfully market our services and implement our business plan.


Although we organized Enterprise in 1986, we did not become active until 1995 and have been continually developing our MedCare Program since that time. As a result, our business is subject to the risks inherent in the establishment of a new business. Specifically, in formulating our business plan, we have relied on the judgment of our officers, directors and consultants but have not conducted any formal independent market studies concerning the demand for our services.


We have had limited revenues since inception. In 2003, we had zero revenues. We have not been profitable, experiencing an accumulated loss of $14,108,549 through December 31, 2003. Even if we become profitable in the future, we cannot accurately predict the level of, or our ability to sustain profitability. Because we have not yet been profitable and cannot predict any level of future profitability, you bear the risk of a complete loss of your investment in the event our business plan is unsuccessful.


Inability to Obtain Funding


We may not be able to obtain additional funding when needed, which could limit future expansion and marketing opportunities, as well as result in lower than anticipated revenues. We may require additional financing to pursue relationships with joint venture partners for the MedCare Program and other business opportunities. If the market price of the common stock declines, some potential financiers may either refuse to offer us any financing or will offer financing at unacceptable rates or unfavorable terms. If we are unable to obtain financing on favorable terms, or at all, this unavailability could prevent us from expanding our business, which could materially impact our future potential revenues.


Continued Control by Existing Management


You may lack an effective vote on corporate matters and management may be able to act contrary to your objectives. As of March 24, 2004, our officers and board members own 80% of the 161,223,308 of our outstanding common stock. If management votes together, it could influence the outcome of corporate actions requiring shareholder approval, including the election of directors, mergers and asset sales. As a result, new stockholders may lack an effective vote with respect to the election of directors and other corporate matters. Therefore, it is possible that management may take actions with respect to its ownership interest, which may not be consistent with your objectives or desires.


Dividends


We have not paid and do not currently intend to pay dividends, which may limit the current return you may receive on your investment in our common stock.  Since inception, we have paid no dividends to our stockholders. Future dividends on our common stock, if any, will depend on our future earnings, capital requirements, financial condition and other factors. We currently intend to retain earnings, if any, to increase our net worth and reserves. Therefore, we do not anticipate that any holder of common stock will receive any cash, stock or other dividends on his shares of common stock at any time in the near future. You should not expect or rely on the potential payment of dividends as a source of current income.


Dependence on Executive Officers and Technical Personnel


The success of our business plan depends on attracting qualified personnel, and failure to retain the necessary personnel could adversely affect our business. Competition for qualified personnel is intense, and we may need to pay premium wages to attract and retain personnel. Attracting and retaining qualified personnel is critical to our business. Inability to attract and retain the qualified personnel necessary would limit our ability to implement our business plan successfully.


Adverse Effect of Shares Eligible for Future Sale


Future sales of large amounts of common stock could adversely affect the market price of our common stock and our ability to raise capital.


Future sales of our common stock by existing stockholders pursuant to Rule 144 under the Securities Act, or following the exercise of outstanding options and warrants, could adversely affect the market price of our common stock. Substantially all of the outstanding shares of our common stock are freely tradable, without restriction or registration under the Securities Act, other than the sales volume restrictions of Rule 144 applicable to shares held beneficially by persons who may be deemed to be affiliates. Our directors and executive officers and their family members are not under lockup letters or other forms of restriction on the sale of their common stock. The issuance of any or all of these additional shares upon exercise of options or warrants or conversion of preferred stock will dilute the voting power of our current stockholders on corporate matters and, as a result, may cause the market price of our common stock to decrease. Further, sales of a large number of shares of common stock in the public market could adversely affect the market price of the common stock and could materially impair our future ability to generate funds through sales of common stock or other equity securities.


Protection of Proprietary Treatment Program


Our ability to effectively compete depends on protection of our proprietary treatment protocol through confidentiality and non-compete agreements.


Our ability to compete will depend, in part, on our ability to develop and maintain the proprietary aspects of our unpatented treatment protocol. We have developed this protocol through our experiences to date in the clinical, billing and marketing areas of incontinence treatment. Others may independently develop the same or a similar program or otherwise obtain access to this protocol from former employees or former MedCare Program physicians.


In addition, third parties have published clinical studies regarding the benefits of biofeedback treatment of incontinence. Although this is only one component of our treatment protocol, others may utilize these clinical studies to begin their own incontinence programs.


We protect our treatment protocols from duplication through our confidentiality and non-compete agreements. We cannot ensure that these agreements will provide meaningful protection for our treatment protocol in the event of their expiration or unauthorized use or disclosure. If our treatment protocol became widely duplicated, larger, better-capitalized companies could instantly compete with us in the incontinence treatment market.


Government Regulation


Unfavorable governmental regulation in the future could threaten our viability. Our business is heavily regulated. The MedCare Program is subject to regulation under the Federal Anti-Kickback Statute and the Federal Self- Referral Statute. In addition, legislators continually enact new legislation. The process of obtaining regulatory approvals can be lengthy and expensive, and the issuance of these approvals is uncertain. Currently, we believe that we are in compliance with all currently existing regulations that apply to us. However, if the federal or state government were to enact any new regulations, we may not be able to obtain the necessary approvals on a timely basis, or at all. Should legislators enact new legislation that is unfavorable to our business, this could, among other things, result in fines, suspensions of regulatory approvals, operating restrictions and criminal prosecution. We cannot predict whether any new reforms will be enacted, the types of approvals that will be required, or the effect of any enacted reform on our business.


Potential Fluctuations in Quarterly Results


Significant variations in our quarterly operating results may adversely affect the market price of our common stock.  Our operating results have varied on a quarterly basis during our limited operating history, and we expect to experience significant fluctuations in future quarterly operating results. These fluctuations have been and may in the future be caused by numerous factors, many of which are outside of our control. We believe that period-to-period comparisons of our results of operations will not necessarily be meaningful and that you should not rely upon them as an indication of future performance. Also, it is likely that our operating results could be below the expectations of public market analysts and investors. This could adversely affect the market price of our common stock.


Competition


In the evolving healthcare field, if we do not continually develop the MedCare Program, and any other future business opportunities, our services could become uncompetitive or obsolete.   Healthcare is a rapidly evolving field in which other companies may have greater financial and research and development resources than we do. The MedCare Program competes directly with a number of small incontinence clinics, offered by doctors, hospitals and therapists, which use a combination of non-invasive alternative treatment options to treat urinary incontinence. In addition, other alternative treatments for urinary incontinence are available to consumers, including absorbent products and diapers, surgery, indwelling catheters, implanting devices, injectable materials, electrical stimulation, mechanical devices and drugs.


Intellectual Property and Other Proprietary Rights


The Company's ability to compete and expand effectively will depend, in part, on its ability to develop and maintain certain proprietary aspects of its treatment program for bladder and bowel incontinence. The Company relies on an unpatented treatment protocol, and there can be no assurances that others may not independently develop the same or similar program or otherwise obtain access to the Company's unpatented protocols. There can be no assurance that any confidentiality agreements between the Company and its employees will provide meaningful protection for the Company's trade secrets, know-how or other information in the event of any unauthorized use or disclosure of such trade secrets, know-how or other proprietary information. While certain proprietary aspects of Enterprise's clinical and business protocols remain an important part of the business, the Company believes its long-term success, as a business will depend primarily upon its high quality clinical outcomes and service and its success in seeking a suitable joint venture partner to further market the MedCare Program.


Environmental Matters


The Company believes it conducts its business in compliance with all environmental laws presently applicable to its facilities. To date, there have been no expenses incurred by the Company related to environmental issues.


ITEM 2.  DESCRIPTION OF PROPERTY


The Company’s principal office is located at 1628 West First Avenue, Suite 216, Vancouver, British Columbia, Canada, V6J 1G1. These premises are owned by a private corporation controlled by a director and majority shareholder. At present, the Company pays no rent. The fair value of the rent has not been included in the financial statements because the amount is immaterial.

ITEM 3.  LEGAL PROCEEDINGS


The Company is not party to any current legal proceedings.


ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS


There were no matters submitted to a vote of the security holders in the fourth quarter of 2003. It is our intention to schedule a shareholder’s meeting to elect directors and transact any additional business in the second or third quarter of 2004.




PART II


ITEM 5.  MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS


Market Information

 

The Company's Common Stock is listed on the OTC Bulletin Board under the symbol "ETPT". The following table sets forth the high and low sale prices for the periods indicated:


 

High

Low

First Quarter 2002

$  0.04

$  0.01

Second Quarter 2002

$  0.03

$  0.02

Third Quarter 2002

$  0.02

$  0.01

Fourth Quarter 2002

$  0.02

$  0.01


First Quarter 2003

$  0.03

$  0.02

Second Quarter 2003

$  0.06

$  0.01

Third Quarter 2003

$  0.49

$  0.04

Fourth Quarter 2003

$  0.58

$  0.25

January 1, 2004-March 25, 2004

$  0.55

$  0.34


As of February 25, 2004, there were approximately 290 stockholders of record of the Company's Common Stock.


Dividend Policy


We have never paid cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future, but intend to retain our capital resources for reinvestment in our business. Any future determination to pay cash dividends will be at the discretion of the Board of Directors and will be dependent upon our financial condition, results of operations, capital requirements and other factors as the Board of Directors deems relevant. Our Board of Directors has the right to authorize the issuance of preferred stock, without further shareholder approval, the holders of which may have preferences over the holders of the Common Stock as to payment of dividends.


Securities Authorized for Issuance Under Equity Compensation Plans



Number of securities

remaining available for

Number of Securities to be

Weighted-average exercise

future issuance under

issued upon exercise of

price of outstanding

equity compensation plans

outstanding options,

options, warrants and

(excluding securities

warrants and rights

rights

reflected in column (a))

Plan Category

(a)

(b)

(c)

____________________________________________________________________________________________________________


Equity compensation plans

approved by security holders

33,478,571

$0.09

5,250,000


Equity compensation plans not

approved by security holders


____________________________________________________________________________________________________________

Total

33,478,571

$0.09

5,250,000



ITEM 6.   MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS


The following discussion should be read in conjunction with the financial statements and notes thereto included in Item 7 of this Form 10-KSB. Except for the historical information contained herein, the discussion in this Annual Report on Form 10-KSB contains certain forward-looking statements that involve risk and uncertainties, such as statements of the Company's plans, objectives, expectations and intentions as of the date of this filing. The cautionary statements made in this document should be read as being applicable to all related forward-looking statements wherever they appear in this document. The Company's actual results could differ materially from those discussed here. Factors that could cause differences include those discussed in "Risk Factors", as well as discussed elsewhere herein.


Overview


Enterprise Technologies, Inc. (the "Company" or "Enterprise") pioneered the MedCare Program, a non-invasive, non-pharmaceutical treatment program for patients suffering from urinary incontinence and other pelvic disorders, including pelvic pain, chronic constipation, fecal incontinence and disordered defecation.

Enterprise is currently (1) searching for potential joint venture partners that have existing operating infrastructures to which the MedCare Program can be added as an ancillary service and (2) is seeking to develop additional revenue streams through the further development and commercial exploitation of the Company's current intellectual property base and or the acquisition of additional technologies.

The Company, a Nevada Corporation, has an authorized capital of 301,000,000 shares of which 300,000,000 shares are $0.00001 par value common stock, 161,223,308 outstanding, and 1,000,000 shares are $0.25 par value preferred stock, of which none are outstanding.

Results of Operations


Revenues:  As a result of the Company terminating its various MedCare Program sites in order to reduce operating expenses in March 2001, during 2003 and 2002 the Company generated zero revenues.


General and Administrative Expenses:  During 2003, the Company incurred $290,333 in general and administrative expenses, an increase of 62% over 2002 expenses of $179,744. The increase is primarily attributable to website development costs, and the retention of a financial and media relations firm to assist in the Company in shareholder and industry awareness programs.


Interest Income:  Interest income was $392 and $233 for the years ended December 31, 2003, and 2002, respectively. Interest earned in the future will be dependent on Company funding cycles and prevailing interest rates.


Discontinued Operations:  During 2003, the Company did not record a loss or a gain from discontinued operations.  During 2002, the Company recorded a gain of $259,028 from discontinued operations when it wrote off all liabilities relating to its subsidiary, RxSheets.com, Inc., which included a balance of $163,621 due under a capital lease and $95,407 in various other accrued liabilities incurred by RxSheets.com.


Provision for Income Taxes:  As of December 31, 2003, the Company's accumulated deficit was $14,108,549, and as a result, there has been no provision for income taxes to date.


Preferred Stock Deemed Dividends:  Preferred stock deemed dividends were $0 for the years ended December 31, 2003 and 2002, respectively.


Net Income:  For the year ended December 31, 2003, the Company recorded a net loss of $289,941 compared to net income of $79,517 for the same period in 2002. Asset liquidation and discontinued operations of the MedCare Program clinics produced an extra-ordinary one time net income in 2002, without the extra-ordinary gains and operational costs resulted in an increased loss in 2003.


Liquidity and Capital Resources


At December 31, 2003, the Company had a cash balance of $97,646 compared to a cash balance of $138,704 at December 31, 2002.


During 2003, the Company used $41,058 of net cash from operating activities, as compared to $33,756 of net cash used in 2002.


Net cash provided by financing activities was $0 for 2003 compared to $165,700 for 2002. The Company has financed its operations primarily through loans from shareholders and private placements of Common Shares.


Plan of Operation


The Company’s cash requirements for the next twelve months will be provided by loans from shareholders or debt/equity financings, if necessary.  The Company's future funding requirements will depend on numerous factors. These factors include the Company's ability to search out and enter into suitable joint venture partnerships in order to further market the MedCare Program or the outright sale of the MedCare Program, to seek out additional revenue streams from the Company’s current intellectual property base and from other technology-based ventures, to recruit and train qualified management personnel and the Company's ability to compete against other, better capitalized corporations who offer similar services.


Due to the "start up" nature of the Company's businesses, the Company expects to incur losses as it expands. The Company expects to raise additional funds through private or public equity investment in order to expand the range and scope of its business operations. The Company will seek access to private or public equity but there is no assurance that such additional funds will be available for the Company to finance its operations on acceptable terms, if at all. See "Risk Factors" for additional details.


Related Party Transactions


Management and Consulting Fees:  During 2003, the Company incurred $29,000 (2002 - $144,000) in management and consulting fees to directors, of which $27,000 was to a director and a major stockholder. Of the amount incurred in 2002, $108,000 was converted to 15,428,571 common stock of the Company at $0.007 per share on September 20, 2002, being the fair market price of the shares. As at December 31, 2003, $63,000 (2002 - $36,000) is included in Accounts Payable-Related Party.


Shareholder Advances:  During 2002, $15,700 was advanced by a director and majority stockholder to help pay for operating expenses. In 2003, The Company recorded imputed interest of $628 (2002 – $0) at an interest rate of 4% per annum.  As of December 31, 2003, this amount remained outstanding and is included in current liabilities.   On February 26, 2004, the entire balance was repaid in full.


Common Stock and Warrants:  On September 20, 2002, the Company accepted a private placement of $150,000 from three entities that are controlled by the two brothers and the father of a director and majority stockholder of the Company. The private placement involved the issuance of 21,428,571 restricted common stocks at $0.007 per stock, being the fair market price of the shares at the date of issuance, and 21,428,571 purchase warrants to acquire common stocks of the Company at $0.007 per stock until September 20, 2005. All of the warrants remain outstanding as of December 31, 2003.


Property:  The Company’s principal office is located at 1628 West First Avenue, Suite 216, Vancouver, British Columbia, Canada, V6J 1G1. These premises are owned by a private corporation controlled by a director and majority shareholder. At present, the Company pays no rent. The fair value of the rent has not been included in the financial statements because the amount is immaterial.


Going Concern


The Company has incurred net operating losses since inception. The Company faces all the risks common to companies in their early stages of development, including under capitalization and uncertainty of funding sources, high initial expenditure levels, uncertain revenue streams, and difficulties in managing growth. The Company’s recurring losses raise substantial doubt about its ability to continue as a going concern.  The Company’s financial statements do not reflect any adjustments that might result from the outcome of this uncertainty. The Company expects to incur losses from its business operations and will require additional funding during 2004. The satisfaction of our cash hereafter will depend in large part on the Company’s ability to successfully raise capital from external sources to pay for planned expenditures and to fund operations.




ITEM 7.

FINANCIAL STATEMENTS



Index to Financial Statements




Independent Auditors’ Report from Moore Stephens Ellis Foster

21


Independent Auditors’ Report from Clancy and Co., PLLC

22


Balance Sheet as of December 31, 2003

23


Statements of Changes in Stockholders’ Equity for the period from inception

to December 31, 2003

 

24


Statements of Operations for years ended December 31, 2003 and 2001, and

for the period from inception to December 31, 2002

 

25



Statements of Cash Flows for the years ended December 31, 2003 and 2002,

and for the period from inception to December 31, 2002

26


Notes to the Financial Statements

27-35






MOORE STEPHENS ELLIS FOSTER LTD.

 CHARTERED ACCOUNTANTS


1650 West 1st Avenue

Vancouver, BC  Canada   V6J 1G1

Telephone:  (604) 734-1112  Facsimile: (604) 714-5916


Website:  www.ellisfoster.com




REPORT OF INDEPENDENT AUDITORS



To the Board of Directors and Stockholders of


ENTERPRISE TECHNOLOGIES, INC. & SUBSIDIARIES



We have audited the consolidated balance sheet of Enterprise Technologies, Inc. & Subsidiaries (“the Company”) as at December 31, 2003 and the related consolidated statements of stockholders’ equity, operations and deficit and cash flows for the year ended December 31, 2003.  These financial statements are the responsibility of the Company's management.  Our responsibility is to express an opinion on these financial statements based on our audit.


We conducted our audit in accordance with auditing standards generally accepted in the United States of America.  Those standards require that we plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement.  An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.  An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audit provide a reasonable basis for our opinion.


In our opinion, these consolidated financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2003 and the results of its operations and its cash flows for the year then ended in conformity with generally accepted accounting principles in the United States of America.  


The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.  As discussed in Note 1 to the financial statements, the Company has incurred significant recurring net losses resulting in a substantial accumulated deficit, which raise substantial doubt about its ability to continue as a going concern.  Management’s plans regarding the matters that raise substantial doubt about the Company’s ability to continue as a going concern are also disclosed in Note 1 to the financial statements.  The ability to meet its future financing requirements and the success of future operations cannot be determined at this time.  These financial statements do not include any adjustments that might result from the outcome of this uncertainty.




Vancouver, Canada

MOORE STEPHENS ELLIS FOSTER LTD.”

March 15, 2004

Chartered Accountants







INDEPENDENT AUDITORS' REPORT


To the Board of Directors and Stockholders of

Enterprise Technologies, Inc.


We have audited the accompanying consolidated statement of operations, changes in stockholders’ equity, and cash flows for the year ended December 31, 2002 of Enterprise Technologies, Inc. (a Nevada corporation) and Subsidiaries. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.


We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.


In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated results of operations and cash flows of Enterprise Technologies, Inc. and Subsidiaries for the year ended December 31, 2002, in conformity with accounting principles generally accepted in the United States of America.


The accompanying financial statements have been prepared assuming the Company will continue as a going concern.  As discussed in Note 2 to the financial statements, the Company has incurred significant recurring net losses since inception and a significant accumulated deficit.  The ability to meet its future financing requirements and the success of future operations cannot be determined at this time. These factors raise substantial doubt about its ability to continue as a going concern.  These financial statements do not include any adjustments that might result from the outcome of this uncertainty.



Clancy and Co., P.L.L.C.

Phoenix, Arizona


February 11, 2003



ENTERPRISE TECHNOLOGIES, INC.

  

& SUBSIDIARIES

  
    

Consolidated Balance Sheets

  

December 31, 2003

  

(Expressed in U.S. Dollars)

  
   

2003

    

ASSETS

   
    

Current assets

  

  Cash and cash equivalents

$

97,646

    

Total assets

 

$

97,646

    

LIABILITIES AND STOCKHOLDERS' EQUITY

  
    

Current liabilities

  

  Accounts payable – related party

$

63,000

  Accounts payable

 

7,800

  Advances from stockholder – related party

 

15,700

    

Total liabilities

 

86,500

    

Commitments and contingencies

  
    

Stockholders' Equity

  

  Preferred stock (authorized: 1,000,000 shares):

  

    convertible series B, $0.25 par value

 

-

  issued and outstanding: nil

  

  Common stock: $0.00001 par value; Authorized: 300,000,000

 

    issued and outstanding: 161,223,308 (2002 - 160,323,308)

 

1,612

  Additional paid-in capital

 

14,118,083

  Accumulated deficit

 

(14,108,549)

    

Total stockholders' equity

 

11,146

    

Total liabilities and stockholders' equity

$

97,646

    

The accompanying notes are an integral part of these financial statements.





ENTERPRISE TECHNOLOGIES, INC.

            

& SUBSIDIARIES

             
              

Consolidated Statements of Stockholders' Equity

            

(Expressed in U.S. Dollars)

             
         

Compre-

 

Accumulated

Total

    

Additional

 

Accumulated

 

hensive

 

other

 

stock-

 

Common shares

 

paid-in

 

earnings

 

income

comprehensive

holders'

 

Shares

Amount

 

capital

 

(deficit)

 

(loss)

 

income

 

equity

              

Balance, December 31, 2001

123,466,166

$

1,235

$

13,643,832

$

(13,898,125)

$

 

$

-

$

(253,058)

Common stock issued for services rendered

15,428,571

 

154

 

107,846

 

-

     

108,000

Common stock issued under private placement

21,428,571

 

214

 

149,786

 

-

     

150,000

Net income, year ended December 31, 2002

-

 

-

 

-

 

79,517

 

79,517

   

79,517

Total comprehensive income  

       

$

79,517

    

Balance, December 31, 2002

160,323,308

 

1,603

 

13,901,464

 

(13,818,608)

   

-

 

84,459

Common stock issued for services rendered

900,000

 

9

 

215,991

 

-

     

216,000

Imputed interest

    

628

       

628

Loss, year ended December 31, 2003

-

 

-

 

-

 

(289,941)

 

(289,941)

   

(289,941)

Total comprehensive (loss)

       

$

(289,941)

    
              

Balance, December 31, 2003

161,223,308

$

1,612

$

14,118,083

$

(14,108,549)

  

$

-

$

11,146

              

The accompanying notes are an integral part of these financial statements.

      





ENTERPRISE TECHNOLOGIES, INC.

  

& SUBSIDIARIES

    
     

Consolidated Statements of Operations and Deficit

    

(Expressed in U.S. Dollars)

    
  

2003

 

2002

     

Revenue

$

-

$

-

     

General and administrative expenses

    

  Management and consulting fees

    

    - related party

 

29,000

 

144,000

  Investors relations

 

227,036

 

-

  Other operating expenses

 

34,297

 

35,744

     

Total general and administrative expenses

 

290,333

 

179,744

     

Operating loss

 

(290,333)

 

(179,744)

     

Interest income

 

392

 

233

     

Loss before income taxes

 

(289,941)

 

(179,511)

     

Provision for income taxes

 

-

 

-

     

Gain (loss) on discontinued operations,

    

  net of tax

 

-

 

259,028

     

Net income (loss) for the year

 

(289,941)

 

79,517

     

Preferred Stock Deemed Dividends

 

-

 

-

     

Net income (loss)

$

(289,941)

$

79,517

     

Earnings (loss) per share

    

  of common stock

    

  - basic and diluted

$

(0.00)

 $

0.00

     

Basic weighted average number

    

  of common stocks outstanding

    

  - basic and diluted

 

160,455,226

 

135,179,669

     

The accompanying notes are an integral part of these financial statements.




ENTERPRISE TECHNOLOGIES, INC.

  

& SUBSIDIARIES

    
     

Consolidated Statements of Cash Flows

    

(Expressed in U.S. Dollars)

    
  

2003

 

2002

     

Cash flows from (used in) operating activities

   

  Net income (loss) for the year

$

(289,941)

$

79,517

  Adjustments to reconcile net income (loss) to

   

    net cash used in operating activities:

    

  - net assets (liabilities) of discontinued

    

      operations

 

-

 

(259,028)

  - common stock issued for services

    

      by conversion of debt

 

-

 

108,000

  - common stock issued for services rendered

216,000

 

-

  - imputed interest on advances to shareholder

628

 

-

  Changes in assets and liabilities:

    

  - increase in accounts payable

    

      and accrued liabilities

 

32,255

 

37,755

     

Net cash used in operating activities

 

(41,058)

 

(33,756)

     

Cash flows provided by financing activities

    

  Loans from stockholders

 

-

 

15,700

  Proceeds from the sale of common stock

 

-

 

150,000

     

Net cash provided by financing activities

 

-

 

165,700

     

Increase (decrease) in cash and

    

  cash equivalents

 

(41,058)

 

131,944

     

Cash and cash equivalents,

    

  beginning of year

 

138,704

 

6,760

     

Cash and cash equivalents, end of year

$

97,646

$

138,704

     

Supplemental non-cash investing and

    

financing activities:

    
     

  Common stock issued for services by

    

    conversion of debt

$

-

$

108,000

  Common stock issued for services

$

216,000

$

-

     

The accompanying notes are an integral part of these financial statements.


ENTERPRISE TECHNOLOGIES, INC.


Notes to Financial Statements

Years Ended December 31, 2003 and 2002

(Expressed in U.S. Dollars)

1.

Organization and Nature of Operations

Enterprise Technologies, Inc. (the “Company” or “Enterprise”), a Nevada Corporation, has an authorized capital of 301,000,000 shares of which 300,000,000 shares are $0.00001 par value common stock and 1,000,000 shares are $0.25 par value preferred stock.

The Company is the developer of the MedCare Program, a non-invasive, non-pharmaceutical treatment program for patients suffering from urinary incontinence and other pelvic disorders, including pelvic pain, chronic constipation, fecal incontinence and disordered defecation. The Company is currently searching for potential joint venture partners that have existing operating infrastructures to which the MedCare Program can be added as an ancillary service with minimal overhead. The Company plans to develop additional revenue streams from the Company's current intellectual property base and other technology-based ventures.

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplates continuation of the Company as a going concern. However, the Company has sustained substantial operating losses in recent years resulting in a substantial accumulated deficit.  In view of these matters, realization of a major portion of the assets in the accompanying balance sheet is dependent upon the continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financing requirements, and the success of its future operations.

To meet these objectives, the Company plans to seek additional equity and expects to raise funds through private or public equity investment in order to support existing operations and expand the range and scope of its business. There is no assurance that such additional funds will be available for the Company on acceptable terms, if at all. Management believes that actions presently taken to revise the Company’s operating and financial requirements provide the opportunity for the Company to continue as a going concern. The Company’s ability to achieve these objectives cannot be determined at this time.

2.

Significant Accounting Policies

(a)

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, MedCare Technologies Corporation and RxSheets.com, Inc.  All intercompany transactions have been eliminated in consolidation.

(b)

Accounting Method

The Company uses the accrual method of accounting for financial statement and tax return purposes.

(c)

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management makes its best estimate of the ultimate outcome for these items based on historical trends and other information available when the financial statements are prepared. Changes in estimates are recognized in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available to management. Actual results could differ from those estimates.

(d)

Cash and Cash Equivalents

The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents for the year ended December 31, 2003.

(e)

Concentration of Credit Risk

The Company maintains U.S. Dollar cash balances in Canadian banks that are not insured.

(f)

Fair Value of Financial Instruments

For certain of the Company’s financial instruments, including cash and cash equivalents, accounts payable and related party accounts payable, and stockholder loans, carrying amounts approximate fair value due to their short maturities.

(g)

Impairment and Disposal of Long-Lived Assets

Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not be recoverable in accordance with the  guidance established in Statement of Financial Accounting Standards (“SFAS”) No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets.  For assets that are to be held and used, an impairment loss is recognized when the estimated undiscounted cash flows associated with the asset or group of assets is less than their carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Fair values are determined based on discounted cash flows or internal and external appraisals, as applicable. Assets to be disposed of are carried at the lower of carrying value or estimated net realizable value.

(h)

Income Taxes

The Company accounts for income taxes under the provisions of SFAS No. 109, “Accounting for Income Taxes.” Under SFAS No. 109, deferred income tax assets and liabilities are computed for differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary, to reduce deferred income tax assets to the amount expected to be realized.

(i)

Earnings (Loss) Per Share

Basic earnings (loss) per share is based on the weighted average number of common shares outstanding. Diluted earnings (loss) per share is based on the weighted average number of common shares outstanding and dilutive common stock equivalents. Basic earnings (loss) per share is computed by dividing income (loss)  (numerator) applicable to common stockholders by the weighted average number of common stocks outstanding (denominator) for the period. All earnings (loss) per share amounts in the financial statements are basic earnings (loss) per share, as defined by SFAS No. 128, “Earnings Per Share.” Diluted earnings (loss) per share does not differ materially from basic earnings per share for all periods presented. Convertible securities that could potentially dilute basic earnings (loss) per share in the future, such as options and warrants, are not included in the computation of diluted earnings (loss) per share because to do so would be antidilutive.

(j)

Stock-Based Compensation

The Company accounts for employee stock-based compensation using the intrinsic value method prescribed in Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees.” Compensation cost for stock options, if any, is measured as the excess of the quoted market price of the Company’s stock at the date of grant over the amount an employee must pay to acquire the stock. SFAS No.123, “Accounting for Stock-Based Compensation,” established accounting and disclosure requirements using a fair-value-based method of accounting for stock-based employee compensation plans. The Company has elected to remain on its current method of accounting as described above, and has adopted the disclosure requirements of SFAS No. 123.

(k)

Comprehensive Income (Loss)

The Company has adopted Statement of Financial Accounting Standards No. 130 (SFAS 130), Reporting Comprehensive Income, which establishes standards for reporting and display of comprehensive income, its components and accumulated balances.  The Company is disclosing this information on its Statement of Stockholders’ Equity.  Comprehensive income (loss) comprises equity except those resulting from investments by owners and distributions to owners.

(l)

Foreign Currency Translation

Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the local functional currency are included in the results of operations.

(m)

Start-up Expenses

The Company expenses start-up costs and organization costs for financial statement purposes pursuant to AICPA Statement of Position 98-5, “Reporting on the Costs of Start-up Activities.” For income tax purposes, the Company has elected to treat its organizational costs as deferred expenses and amortize them over a period of sixty months, beginning in the first month the Company is actively in business.

(n)

Accounting for Derivative Instruments and Hedging Activities

The Company adopted Statement of Financial Accounting Standards Board No. 133 (SFAS 133), Accounting for Derivative Instruments and Hedging Activities,  which requires companies to recognize all derivatives contracts as either assets or liabilities in the balance sheet and to measure them at fair value.  If certain conditions are met, a derivative may be specifically designated as a hedge, the objective of which is to match the timing of gain or loss recognition on the hedging derivative with the recognition of (i) the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk or (ii) the earnings effect of the hedged forecasted transaction.  For a derivative not designated as a hedging instrument, the gain or loss is recognized in income in the period of change.

The Company has not entered into derivative contracts either to hedge existing risks or for speculative purposes.  The option of this pronouncement does not have an impact on the Company’s financial statements.

(o)

Intangible Assets

On January 1, 2002, the Company adopted the Statement of Financial Accounting Standards No. 142 (SFAS 142), Goodwill and Other Intangible Assets”, which requires that goodwill and intangible assets with indefinite life are not amortized but rather tested at least annually for impairment.  Intangible assets with a definite life are required to be amortized over its useful life or its estimated useful life.

As at December 31, 2003, the Company did not have any goodwill or intangible assets with indefinite or definite life.

(p)

Related Party Transactions

A related party is generally defined as (i) any person that holds 10% or more of the Company’s securities and their immediate families, (ii) the Company’s management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties (See Note 3).

(q)

Reclassification

Certain prior period amounts have been reclassified to conform to the current year presentation. There was no effect on previously reported results of operations or total stockholders’ equity.

(r)

New Accounting Pronouncements

In November 2002, the FASB issued Interpretation No. 45 (FIN 45), “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others – An Interpretation of FASB Statements No. 5, 57, and 107 and rescission of FASB Interpretation No. 34.” This interpretation clarifies the requirements for a guarantor’s accounting for and disclosures of certain guarantees issued and outstanding. FIN 45 also clarifies the requirements related to the recognition of a liability by a guarantor at the inception of a guarantee. FIN 45 is effective for guarantees entered into or modified after December 31, 2002. The adoption of FIN 45 does not have an impact on the Company’s financial statements.

In January 2003, the FASB released FASB Interpretation No. 46 (“FIN 46”), Consolidation of Variable Interest Entities. FIN 46 requires that all primary beneficiaries of variable interest entities consolidate that entity. FIN 46 is effective immediately for variable interest entities created after January 31, 2003 and to variable interest entities in which an enterprise obtains an interest after that date. It applies in the first fiscal year or interim period beginning after June 15, 2003 to variable interest entities in which an enterprise holds a variable interest it acquired before February 1, 2003. In December 2003, the FASB published a revision to FIN 46 (“FIN 46R”) to clarify some of the provisions of the interpretation and to defer the effective date of implementation for certain entities. Under the guidance of FIN 46R, entities that do not have interests in structures that are commonly referred to as special purpose entities are required to apply the provisions of the interpretation in financial statements for periods ending after March 14, 2004. The Company did not create a variable interest entity after January 31, 2003 and does not have a variable interest entity as of December 31, 2003. The Company expects that the full adoption of FIN 46R in 2004 will not have a material impact on the Company’s financial position or results of operations

In May 2003, the FASB issued SFAS No. 149, Amendment of Statement 133 on Derivative Instruments and Hedging Activities.   SFAS No. 149 addresses certain accounting issues related to hedging activity and derivative instruments embedded in other contracts.  In general, the amendments require contracts with comparable characteristics to be accounted for similarly.  In addition, SFAS No. 149 provides guidance as to when a financing component of a derivative must be given special reporting treatment in the statement of cash flows.  SFAS No. 149 is effective for contracts entered into or modified after June 30, 2003. The adoption of SFAS No. 149 does not have an impact on the Company’s financial statements.

In May 2003, the Financial Accounting Standards Board (FASB) approved SFAS No. 150, Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity.  SFAS No. 150 establishes standards for how to classify and measure financial instruments with characteristics of both liabilities and equity. It requires financial instruments that fall within its scope to be classified as liabilities. SFAS No. 150 is effective for financial instruments entered into or modified after May 31, 2003 and, for pre-existing financial instruments, as of July 1, 2003. The Company does not have any financial instruments that fall under the guidance of SFAS No. 150 and, therefore, the adoption does not have any effect on the Company’s consolidated financial statements.

3.

Related Party Transactions

(a)

Management and Consulting Fees

During 2003, the Company incurred $29,000 (2002 - $144,000) in management and consulting fees to directors, of which $27,000 was to a director and a major stockholder. Of the amount incurred in 2002, $108,000 was converted to 15,428,571 common stock of the Company at $0.007 per share on September 20, 2002, being the fair market price of the shares. As at December 31, 2003, $63,000 is included in Accounts Payable-Related Party.

(b)

Stockholder Advances

During 2002, $15,700 was advanced by a director and majority stockholder to help pay for operating expenses. In 2003, The Company recorded imputed interest of $628 (2002 – $nil) at an interest rate of 4% per annum.  As of December 31, 2003, this amount remained outstanding and is included in current liabilities.   On February 26, 2004, the entire balance was repaid in full.

(c)

Common Stock and Warrants

On September 20, 2002, the Company accepted a private placement of $150,000 from three entities that are controlled by the two brothers and the father of a director and majority stockholder of the Company. The private placement involved the issuance of 21,428,571 restricted common stocks at $0.007 per stock, being the fair market price of the shares at the date of issuance, and 21,428,571 purchase warrants to acquire common stocks of the Company at $0.007 per stock until September 20, 2005. All of the warrants remain outstanding as of December 31, 2003.

(d)

Rent

The Company’s principal office is located at 1628 West First Avenue, Suite 216, Vancouver, British Columbia, Canada.  These premises are owned by a private corporation controlled by a director and majority stockholder. At present, the Company pays no rent. The fair value of the rent has not been included in the financial statements because the amount is immaterial.

4.

Discontinued Operations And Contingent Liability

During May 2000, the Company acquired computer equipment and software under a twenty-four months capital lease, which was leased on behalf of the Company’s former subsidiary RxSheets.com, Inc. (“RxSheets”). On November 10, 2000, the Company sold this computer equipment and software to WGC Enterprises, an investment group. The purchase price was based on the future revenues generated by the acquiring entity over the twenty-four month lease period. The investment group was unable to raise the appropriate funding to continue the operations of RxSheets and as such RxSheets discontinued its operations during the fourth quarter of 2000 due to its high operating costs. The Company closed its offices in March 2001, the equipment was returned to the lessor, and the net book value of the equipment under capital lease of $153,428.

RxSheets’s charter was revoked by the State of Nevada on February 1, 2002. During the fourth quarter of 2002, the Company wrote off all liabilities relating to this subsidiary, which included the balance due under the capital lease of $163,621 and $95,407 of various other accrued liabilities incurred by the subsidiary. There was no tax effect on the transaction due to the Company’s loss position. Because the Company co-signed the capital lease on behalf of RxSheets, the Company is contingently liable for the remaining lease payments. There are no remaining assets or liabilities related to RxSheets.

5.

Common Stock and Warrants

On September 22, 2003, the Company’s Board of Directors agreed to retain National Infosystems Inc. to provide financial and media relations services for an all-inclusive fee of $216,000, which was paid by the issuance of 900,000 restricted common stocks at a price of $0.24 per stock, being the fair market price on September 22, 2003.


See Notes 3(a) and 3(c) for common stocks issued under related party transactions.  


Share purchase warrants outstanding as at December 31, 2003:

Number of Warrants

Exercise Price

Expiry Date

300,000

$5.00

October 14, 2004

4,000,000

$0.05

January 10, 2005

3,000,000

$0.05

March 1, 2005

21,428,571

$0.007

September 20, 2005

28,728,571

  

Each warrant entitles the holder to acquire one common share of the Company.

6.

Stock Options

On July 12, 2001, the Company approved its 2001 Stock Option Plan, which has 10,000,000 stocks reserved for issuance thereunder, all of which were registered under Form S8 on October 2, 2003. The objective of this plan is to attract and retain the best personnel, providing for additional performance incentives and promoting the success of the Company by providing individuals the opportunity to acquire common stock.

On September 22, 2003, the Company’s Board of Directors granted Non-Statutory Stock Options under the 2001 Stock Option Plan to three employees to purchase 4,750,000 common stocks at price of $0.24 per stock, the closing price of the Company’s stocks on September 22, 2003. The options shall become exercisable in two equal installments of fifty percent (50%), with the first installment becoming exercisable upon issuance and the balance becoming exercisable on September 22, 2004.  

Summary of employee stock option information for the period ended December 31, 2003 is as follows:

 


Stocks

Weighted Average

Exercise Price

 


 

Options outstanding at December 31, 2002

90,000

$

4.97

Cancelled

(90,000)

$

(4.97)

Granted

4,750,000

$

0.24

Options outstanding at December 31, 2003

4,750,000

$

0.24



Options Outstanding and Exercisable



Range of

Exercise

Prices




Number

Outstanding




Number exercisable

Weighted

Average

Remaining

Contractual

Life (yr.)


Weighted

Average

Exercise

Price

$0.01 - $0.50

4,750,000

2,375,000

9.70

$   0.24

     

Each stock option entitles the holder to acquire one common stock of the Company.


Had compensation expense for the Company's stock-based compensation plans been determined under SFAS No. 123, based on the fair market value at the grant dates, the Company's pro forma net loss and pro forma net loss per stock would have been reflected as follows:

 

2003

2002

Net income (loss):

  

  As reported

$

(289,941)

$

79,517

    Stock-based employee compensation

  

      expense as determined under the

  

      fair value based method

$

(665,260)

$

 (59,054)

  Pro-forma

$

(955,201)

$

20,463

   

Net income (loss) per stock

  – basic and diluted:

  

  As reported

$

0.00

$

0.00

  Pro-forma

$

(0.01)

$

0.00

   

The weighted average fair value of the options granted was estimated at $0.24 by using the Black-Scholes Option Pricing Model with the following weighted average assumptions: dividend yield of 0%, expected volatility of 159%, risk-free interest rates of 3.5%, and expected lives of five years.

7.

Income Taxes

There is no current or deferred tax expense for the years ended December 31, 2003, 2002 and 2001, due to the Company's loss position. The Company has fully reserved for any benefits of these losses. The deferred tax consequences of temporary differences in reporting items for financial statement and income tax purposes are recognized, as appropriate. Realization of the future tax benefits related to the deferred tax assets is dependent on many factors, including the Company's ability to generate taxable income within the net operating loss carryforward period. Management has considered these factors in reaching its conclusion as to the valuation allowance for financial reporting purposes.

The income tax effect of temporary differences comprising the deferred tax assets and deferred tax liabilities on the accompanying consolidated balance sheet is a result of the following:

 

2003

2002

Deferred taxes:

  

NOL carryforwards

$

4,687,523

$

4,551,523

Valuation allowance

(4,687,523)

(4,551,523)

Net deferred tax assets

$

-

$

-


The net change in the valuation allowance for 2003 was an increase of $136,000 (2002 – decrease of $63,940) which was principally the result of net operating loss carryforwards.

The Company has available net operating loss carryforwards of approximately $13,400,000 for tax purposes to offset future taxable income which expire through 2023. Pursuant to the Tax Reform Act of 1986, annual utilization of the Company’s net operating loss carryforwards may be limited if a cumulative change in ownership of more than 50% is deemed to occur within any three-year period.

A reconciliation between the statutory federal income tax rate (34%) and the effective rate of income tax expense for each of the years during the period ended December 31 follows:

 

2003

2002

 

%

%

Statutory federal income tax rate

(34.0)

(34.0)

Valuation allowance

34.0

34.0

Effective income tax rate

0.0

0.0






ITEM 8: CHANGE IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE


We have had no disagreements with our certified public accountants with respect to accounting practices, procedures or financial disclosure.

ITEM 8a: CONTROLS AND PROCEDURES


Evaluation of Disclosure Controls and Procedures


It is the  Chief  Executive  Officer’s  and the Principal Financial  Officer’s responsibility  to ensure that we maintain  disclosure  controls and  procedures designed  to  provide  reasonable  assurance  that  material  information,  both financial and non-financial, and other information required under the securities laws to be disclosed is identified and  communicated  to senior  management on a timely  basis.  Our disclosure   controls and procedures include periodic management meetings to ensure communication of reportable events, receipt of ongoing advice from legal council and outside auditors on new legislation and updating, if required, the Company’s disclosure controls and procedures.


Changes in Internal Controls


During the fourth quarter of fiscal 2003, the management of the Company, including the Chief Executive Officer and the Principal Financial Officer, evaluated the Company’s disclosure controls and procedures. Under rules promulgated by the SEC, disclosure controls and procedures are defined as those "controls or other procedures of an issuer that are designed to ensure that information required to be  disclosed by the issuer in the reports  filed or  submitted by it under the Exchange Act is recorded,  processed,  summarized and reported, within the time periods  specified  in the  Commission’s  rules and  forms."  There have been no significant changes in internal controls, or in factors that could significantly affect internal controls, subsequent to the date that management, including the Chief Executive Officer and the Principal Financial Officer, completed their evaluation.


ITEM 9: DIRECTORS AND EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT


Set forth below is certain information regarding each of the directors and officers of the Company:


INDY S. PANCHI (Age 39).  CEO, President, Director.  Mr. Indy S. Panchi, received his Bachelor’s degree in Business and Finance from Manchester University in June 1990 and acquired a Post Graduate Diploma in Management Studies from the University of Central England two years later (June, 1992).  In October 1992, he joined the Executive Agency of the Department of Trade and Industry’s British Insolvency Service.   In February 1998, Mr. Panchi was awarded an Executive Officer position with the British Foreign Office’s, Trade Partners UK (formerly, British Trade International).  From June 2000 thru April 2001, Mr. Panchi was self-employed as a business consultant, offering business development and market analysis consulting services to private companies, public corporations and start-up ventures.  In April 2001, Mr. Panchi accepted a position with Kanester Johal, a firm affiliated with Kingston Sorel International. Since July 2002, Mr. Indy Panchi has been working for BDO Dunwoody Ltd, the world’s fifth largest multinational accounting, insolvency and consulting organization. Mr. Panchi joined the Company as a Director and its President and Chief Executive Officer on September 22, 2003.


DEREK J. COOPER (Age 26).  Secretary, Treasurer, Director.  Mr. Derek J. Cooper, the Company’s newly appointed Director, Secretary and Treasurer, earned his Bachelor of Science degree in Physics at the University of British Columbia in May 2001, specializing in solid state and optics.  Subsequently, in April 2002, during his tenure at the diversified mining and metals giant Teck-Cominco, Mr. Cooper co-designed and commissioned a hydrometallurgy extraction process for molybdenum.  In January 2003, Mr. Cooper joined Syncrude Canada Ltd., the world’s largest producer of crude oil from oil sands and the largest single source producer in Canada. Mr. Cooper joined the Company as a director and its Secretary, Treasurer and Director on September 22, 2003.


HARMEL S. RAYAT, (Age 42). Chairman, Director. Mr. Rayat has been in the venture capital industry since 1981. Between January 1993 and April 2001, Mr. Rayat served as the president of Hartford Capital Corporation, a company that provides financial consulting services to emerging growth corporations. From April 2001 through January 2002, Mr. Rayat acted as an independent consultant advising small corporations. Since January 2002, Mr. Rayat has been president of Montgomery Asset Management Corporation, a privately held firm providing financial consulting services to emerging growth corporations. Mr. Rayat is also a Director of Entheos Technologies, Inc., HepaLife Technologies, Inc. and eDeal.net, Inc. Mr. Rayat has served as a Director of the Company since December 4, 2000.


On October 23, 2003, Mr. Harmel S. Rayat, EquityAlert.com, Inc., Innotech Corporation and Mr. Bhupinder S. Mann, a part-time employee of the Company, collectively the respondents, consented to a cease-and-desist order pursuant to Section 8A of the Securities Act of 1933. Without admitting or denying the findings of the Securities and Exchange Commission related to the public relation and stock advertising activities of EquityAlert.com, Inc. and Innotech Corporation, the respondents agreed to cease and desist from committing or causing any violations and any future violations of Section 5(a) and 5(c) of the Securities Act of 1933.  EquityAlert.com, Inc. and Innotech Corporation agreed to pay disgorgement and prejudgment interest of $31,555.14. On August 8, 2000, Mr. Harmel S. Rayat and EquityAlert.com, Inc., without admitting or denying the allegations of the Securities and Exchange Commission that EquityAlert.com, Inc did not disclose certain compensation received by it in connection with stock advertisements and promotions, consented to the entry of a permanent injunction enjoining them from violating Section 17(b) of the Securities Act of 1933; in addition, each agreed to pay a civil penalty of $20,000.


Compliance With Section 16(a) of the Exchange Act


Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), requires the Company's directors, officers and persons who own more than 10 percent of a registered class of the Company's equity securities, to file reports of ownership and changes in ownership with the Securities and Exchange Commission ("the Commission"). Directors, officers and greater than 10 percent beneficial owners are required by applicable regulations to furnish the Company with copies of all forms they file with the Commission pursuant to Section 16(a). Based solely upon a review of the copies of the forms furnished to the Company, the Company believes that during fiscal 2003 the Section 16(a) filing requirements applicable to its directors and executive officers were satisfied.


ITEM 10:  EXECUTIVE COMPENSATION


Remuneration and Executive Compensation


The following table shows, for the three-year period ended December 31, 2003, the cash compensation paid by the Company, as well as certain other compensation paid for such year, to the Company's Chief Executive Officer and the Company's other most highly compensated executive officers. Except as set forth on the following table, no executive officer of the Company had a total annual salary and bonus for 2003 that exceeded $100,000.


Summary Compensation Table

                                                                                  

Securities

                                                                                 

Underlying

Name and                                                                         

Options       

All Other

Principal Position               Year

Salary     

Bonus

Other    

Granted     

Compensation

                                                                                                

Harmel S. Rayat (1)          

2003

 $27,000

$0       

$0           

0

$0

Chairman, Director

2002    

 $144,000

$0        

$0           

0             

$0

                            

2001    

 $149,500       

$0        

$0           

0             

$0


Indy Panchi

            

2003

 $0       

$0

$1,150

0

$0

CEO, President,

     

2002

 $0

$0        

$0           

0             

$0

Director                             

2001

 $0

       

$0        

$0           

0             

$0


Derek Cooper,             

2003

 $0

$0       

$850

0

$0

Secretary, Treasurer,     

2002

 $0

$0        

$0           

0             

$0

Director

2001

 $0

       

$0        

$0           

0             

$0


Ray Krauss (2)             

2003

 $0

$0       

$0           

0

$0

Former CEO, President,    

2002    

 $0

$0        

$0           

0             

$0

Director                             

2001    

 $30,037       

$0        

$0           

0             

$0



Harvinder Dhaliwal (3)

2003

 $0       

$0        

$0          

0         

$0

Former Secretary,

2002

 $0       

$0        

$0          

0              

$0

Treasurer, Director         

2001

 $0       

$0        

$0          

0              

$0


(1) During 2003, the Company incurred $29,000 (2002 - $144,000) in management and consulting fees to directors, of which $27,000 was to a director and a major stockholder. Of the amount incurred in 2002, $108,000 was converted to 15,428,571 common stock of the Company at $0.007 per share on September 20, 2002, being the fair market price of the shares. As at December 31, 2003, $63,000 (2002 - $36,000) is included in Accounts Payable-Related Party.

(2) Resigned as CEO, President and Director on September 22, 2003

(3) Resigned as Secretary, Treasurer and Director on September 22, 2003


Stock Option Grants in Last Fiscal Year


Shown below is further information regarding employee stock options awarded during 2003 to the named officers and directors:


Number of

% of Total

Securities

Options Granted

Underlying

to Employees

   Exercise

  Expiration


Name

Options

in 2002

   Price ($/sh)

  Date



Harmel Rayat

0

0

n/a

n/a

Indy Panchi

0

0

n/a

n/a

Derek Cooper

0

0

n/a

n/a

Ray Krauss (1)

0

0

n/a

n/a

Harvinder Dhaliwal (2)

0

0

n/a

n/a


(1)

Resigned as CEO, President and Director on September 22, 2003

(2)

Resigned as Secretary, Treasurer and Director on September 22, 2003


Aggregated Option Exercises During Last Fiscal Year and Year End Option Values


The following table shows certain information about unexercised options at year-end with respect to the named officers and directors:


Common Shares Underlying Unexercised         Value of Unexercised In-the-money    

                        

Options on December 31, 2003     

Options on December 31, 2003      


Name  

    Exercisable

    Unexercisable

       Exercisable

      Unexercisable


Harmel Rayat

0

0

0

0

Indy Panchi

0

0

0

0


Derek Cooper

0

0

0

0

Ray Krauss (1)

0

0

0

0


Harvinder Dhaliwal (2)

0

0

0

0


(1)

Resigned as CEO, President and Director on September 22, 2003

(2)

Resigned as Secretary, Treasurer and Director on September 22, 2003


Changes in Control

There are no understandings or agreements, aside from the transaction completed and described under “Certain Relationships and Related Transactions,” known by management at this time which would result in a change in control of the Company.  If such transactions are consummated, of which there can be no assurance, the Company may issue a significant number of shares of capital stock which could result in a change in control and/or a change in the Company’s current management.


ITEM 11:  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT


The following table sets forth, as of March 24, 2004, the beneficial ownership of the Company's Common Stock by each director and executive officer of the Company and each person known by the Company to beneficially own more than 5% of the Company's Common Stock outstanding as of such date and the executive officers and directors of the Company as a group.


Number of Shares

Person or Group

of Common Stock

Percent


Harmel S. Rayat (1)

  129,361,471

80%

216-1628 West First Avenue

Vancouver, B.C. V6J 1G1 Canada


Indy Panchi

                    0

0%

216-1628 West First Avenue

Vancouver, B.C.  V6J 1G1 Canada  

 

Derek Cooper

           17,000

0%

216-1628 West First Avenue

Vancouver, B.C.  V6J 1G1 Canada


Directors and Executive Officers

  129,378,471

80%

as a group (3 persons)


(1) Includes 31,300 shares held by Tajinder Chohan, Mr. Rayat's wife. Additionally, other members of Mr. Rayat's family hold 21,559,871 common shares and 21,428,571 share purchase warrants. Mr. Rayat disclaims beneficial ownership of the shares and share purchase warrants beneficially owned by his wife and other family members.


ITEM 12:  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS


Management and Consulting Fees:

During 2003, the Company incurred $29,000 (2002 - $144,000) in management and consulting fees to directors, of which $27,000 was to a director and a major stockholder. Of the amount incurred in 2002, $108,000 was converted to 15,428,571 common stock of the Company at $0.007 per share on September 20, 2002, being the fair market price of the shares. As at December 31, 2003, $63,000 (2002 - $36,000) is included in Accounts Payable-Related Party.


Shareholder Advances:  During 2002, $15,700 was advanced by a director and majority stockholder to help pay for operating expenses. In 2003, The Company recorded imputed interest of $628 (2002 – $0) at an interest rate of 4% per annum.  As of December 31, 2003, this amount remained outstanding and is included in current liabilities.   On February 26, 2004, the entire balance was repaid in full.


Common Stock and Warrants:  On September 20, 2002, the Company accepted a private placement of $150,000 from three entities that are controlled by the two brothers and the father of a director and majority stockholder of the Company. The private placement involved the issuance of 21,428,571 restricted common stocks at $0.007 per stock, being the fair market price of the shares at the date of issuance, and 21,428,571 purchase warrants to acquire common stocks of the Company at $0.007 per stock until September 20, 2005. All of the warrants remain outstanding as of December 31, 2003.


Property:  The Company’s principal office is located at 1628 West First Avenue, Suite 216, Vancouver, British Columbia, Canada, V6J 1G1. These premises are owned by a private corporation controlled by a director and majority shareholder. At present, the Company pays no rent. The fair value of the rent has not been included in the financial statements because the amount is immaterial.


ITEM 13:  EXHIBITS AND REPORTS ON FORM 8-K


(a)  The following exhibits are filed as part of this Annual Report:


10.1*

S-8 Filing on October 2, 2003


31.1

Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)


31.2

Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)


32.1

Certification by the Chief Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002


32.2

Certification by the Chief Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002


* Previously filed


(b)  During the Company’s fourth fiscal quarter, there were no reports filed on Form 8-K

ITEM 14: PRINCIPAL ACCOUNTANT FEES AND SERVICES


The firm of Clancy and Co., P.L.L.C, served as the Company's independent public accountants from inception to September 30, 2003, until their dismissal in January 2004.  The firm of Moore Stephens Ellis Foster Ltd. currently serves as the Company's independent accountants.  The Board of Directors of the Company, in its discretion, may direct the appointment of different public accountants at any time during the year, if the Board believes that a change would be in the best interests of the stockholders.  The Board of Directors has considered the audit fees, audit-related fees, tax fees and other fees paid to the Company's accountants, as disclosed below, and had determined that the payment of such fees is compatible with maintaining the independence of the accountants.


Audit Fees:  The aggregate  fees,  including  expenses,  billed by the Company's principal accountant in connection with the audit of our consolidated  financial statements  for the most recent  fiscal year and for the review of our financial information  included in our Annual  Report on Form  10-KSB;  and our  quarterly reports on Form  10-QSB  during the fiscal  years  ending  December  31, 2003 and December 31, 2002 were $8,617 and $12,460.


Tax fees: The aggregate fees billed to the Company for tax compliance, tax advice and tax planning by the Company’s principal accountant for fiscal 2003 and 2002 were $0 and $1,200.00 respectively.


All Other Fees: The aggregate  fees,  including  expenses,  billed for all other services  rendered to the Company by its principal  accountant  during year 2003 and 2002 were $675.00, in connection with the review of our Form S-8 registration in 2003 and $0 respectively,.    


The Company does not currently have an audit committee.






SIGNATURES


Pursuant to the requirements of Sections 13 or 15 (d) of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,  thereunto duly  authorized on this 8th day of April, 2004.


                                                           

Enterprise Technologies, Inc.




                                                              

/s/ Indy Panchi

                                                              

Indy Panchi

                                                              

Chief Executive Officer




Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons  on  behalf of the registrant and in capacities and on the dates indicated.


       

         

Signature                         

Title                           

Date



/s/ Indy Panchi

Director , President,

April 8, 2004

Indy Panchi

Chief Executive Officer




                                                                      

/s/ Harmel S. Rayat

Director

April 8, 2004

Harmel S. Rayat



/s/ Derek Cooper       

Director, Secretary/Treasurer,   

April 8, 2004

Derek Cooper

 

Principal Financial Officer






Exhibit 31.1


CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002


I, Indy Panchi, certify that:


(1)

 

I have reviewed this quarterly report on Form 10-KSB of Enterprise Technologies, Inc. (the “registrant”);

 

  

(2)

 

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  

(3)

 

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  

(4)

 

The small business issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:


 

(a)

 

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

 

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

 

Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

 

Disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and


(5)

 

The small business issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):


 

(a)

 

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

   

 

(b)

 

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


 

 

 

 

 

Date:  April 8, 2004

 

By:

 

/s/ Indy Panchi

 

 

 

 

Indy Panchi
President and Chief Executive Officer








Exhibit 31.2


CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002


I, Derek Cooper, certify that:


(1)

 

I have reviewed this quarterly report on Form 10-KSB of Enterprise Technologies, Inc. (the “registrant”);

 

  

(2)

 

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  

(3)

 

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  

(4)

 

The small business issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:


 

(a)

 

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

 

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

 

Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

 

Disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and


(5)

 

The small business issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):


 

(a)

 

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

   

 

(b)

 

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


 

 

 

 

 

Date:  April 8, 2004

 

By:

 

/s/ Derek Cooper

 

 

 

 

Derek Cooper
Principal Financial Officer










Exhibit 32.1

Certification by the Chief Executive Officer pursuant to 18 U.S.C. 1350
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002


In connection with the Annual Report of Enterprise Technologies, Inc. (the “Company”) on the Form 10-KSB for the period ending December 31, 2003 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Indy Panchi, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, that:


(i)

the Report filed by the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii)

The information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of the Company on the dates and for the periods presented therein.


 

 

ENTERPRISE TECHNOLOGIES, INC.

 

 

 

 

 

Date:  April 8, 2004

 

By:

 

/s/ Indy Panchi

 

 

 

 

Indy Panchi
President and Chief Executive Officer


This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



Exhibit 32.2

Certification by the Chief Financial Officer pursuant to 18 U.S.C. 1350
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002


In connection with the Annual Report of Enterprise Technologies, Inc. (the “Company”) on the Form 10-KSB for the period ending December 31, 2003 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Derek Cooper, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, that:


(i)

the Report filed by the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii)

The information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of the Company on the dates and for the periods presented therein.


 

 

ENTERPRISE TECHNOLOGIES, INC.

 

 

 

 

 

Date:  April 8, 2004

 

By:

 

/s/ Derek Cooper

 

 

 

 

Derek Cooper

Principal Financial Officer


This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.